The therapeutic approach of immune checkpoint inhibitors has revolutionized the long-term survival of melanoma patients, but has also reached its limits. Innovative approaches such as adoptive T-cell therapy and personalized mRNA vaccines offer new hope. In addition, the neoadjuvant paradigm has shown that the right timing of therapy can be a decisive factor.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- The Brain and the Motivation to Eat
Why is it so hard to lose weight?
- Cardiology and Nutrition
Ultra-Processed Foods and Cardiovascular Risk—The New AHA Position Statement
- Breast (HR+) and Endometrial Cancer
A Comparison of Hormone-Dependent Female Tumors
- Chronic Urticaria: Treatment for Patients Unresponsive to Antihistamines
In addition to anti-IgE antibodies, the guideline recommends anti-IL-4α antibodies and BTK inhibition
- Type 1 Diabetes in Childhood
Early Impairment of Glucagon Counterregulation
- Psychosis in Parkinson's Disease
Be Careful When Choosing Medications
- Esophageal Cancer
A Comparison of Endoscopic and Surgical Innovations
- PMR and LVV: Current EULAR Recommendations